Business
Appointment of Director
Appointment of Director.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n18 August 2011\n\n Scancell Holdings Plc \n\n (`Scancell Holdings' or the `Company') \n\n Appointment of Director \n\nScancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer\nvaccines, is pleased to announce the appointment of Katherine Cornish-Bowden as\na non-executive director with immediate effect.\n\nKate (44) is a Chartered Financial Analyst and holds a Masters in Business\nAdministration. She was managing director and head of Morgan Stanley Investment\nManagement's Global Core Equity Team between 2002 and 2004. Prior to this she\nwas an executive director and senior portfolio manager within the same team at\nMorgan Stanley. More recently Kate has acted as a consultant providing\nfinancial research to private equity and financial training firms and was\nappointed a director of Investec Structured Products Calculus VCT plc in\nFebruary 2011.\n\nKate was formerly a director of KCB Research Limited which was voluntarily\nremoved from the Register of Companies on 12 August 2009.\n\nThere are no other requirements to be disclosed under Schedule Two, paragraph\n(g) of the AIM Rules for Companies.\n\nDavid Evans commented \"I very much welcome Kate onto Scancell's Board, we are\nfortunate to have been able to attract someone of Kate's calibre and she will\nmake an invaluable contribution to the Scancell Board going forward.\"\n\nFor further information contact:\n\nScancell Holdings Plc + 44 (0)207 245 1100 \nProfessor Lindy Durrant/Dr Richard Goodfellow \n \nHansard Communications- Financial PR + 44 (0)207 245 1100 \nAdam Reynolds/Guy McDougall \n \nZeus Capital - Nominated Adviser + 44 (0)161 831 1512 \nRoss Andrews/Tom Rowley \n \nXCAP Securities Plc - Broker +44 (0) 207 101 7070 \nJon Belliss/Parimal Kumar \n\nAbout Scancell\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1, which entered clinical trials\nin 2010, is being developed for the treatment of melanoma.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an immune response. Effective cancer\nvaccines need to target dendritic cells to stimulate both parts of the cellular\nimmune system; the helper cell system where inflammat...